Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Nov-Dec;32(6):664-75.
doi: 10.5555/ajhb.2008.32.6.664.

Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis

Mitchell Nides  1 , Elbert D Glover, Victor I Reus, Arden G Christen, Barry J Make, Clare B Billing Jr, Kathryn E Williams
Affiliations
Randomized Controlled Trial

Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis

Mitchell Nides et al. Am J Health Behav. 2008 Nov-Dec.

Abstract

Objectives: To evaluate varenicline's efficacy for smoking cessation versus bupropion SR and placebo and to explore whether factors typically predictive of abstinence influence varenicline's efficacy versus placebo, as measured by the week 9-12 continuous abstinence rate (CAR9-12).

Methods: Smokers in 2 randomized, placebo-controlled trials received varenicline 1 mg BID (n=696), bupropion SR 150 mg BID (n=671), or placebo (n=685) for 12 weeks. Nontreatment followup lasted 40 weeks.

Results: CAR(9-12) was greater for varenicline (44.0%) versus bupropion SR (29.7%; P<0.0001) and placebo (17.7%; P<0.0001). CAR(9-12) for varenicline versus placebo was not affected by age, gender, or nicotine dependence level.

Conclusions: Varenicline was more efficacious than bupropion SR or placebo. Varenicline's efficacy versus placebo was not influenced by factors predictive of abstinence.

Trial registration: ClinicalTrials.gov NCT00141206 NCT00143364.

PubMed Disclaimer

Publication types

Associated data